Publications by authors named "Juliana Finkelsztejn"
Background: Fampridine is a broad-spectrum voltage-dependent potassium channel blocker that enhances synaptic transmission. The drug has been shown to be able to ameliorate conduction in demyelinated axons, thereby leading to improved gait in patients with multiple sclerosis (MS).
Objective: To assess the "real-life" efficacy and safety of fampridine prescribed for gait disorders in MS.
The real-life experience with cardiovascular complications in the first dose of fingolimod for multiple sclerosis.
Arq Neuropsiquiatr
September 2014
Fingolimod is a new and efficient treatment for multiple sclerosis (MS). The drug administration requires special attention to the first dose, since cardiovascular adverse events can be observed during the initial six hours of fingolimod ingestion. The present study consisted of a review of cardiovascular data on 180 patients with MS receiving the first dose of fingolimod.
View Article and Find Full Text PDFMultiple sclerosis (MS) is one of the leading causes of neurologic deficits in young adults and can lead to physical, intellectual and emotional problems. Approved treatments are expensive and are among the 10 highest budgets of the Brazilian Health Ministry. Given the diverse prevalence of MS among Brazilian regions, it is important to determine prevalence rates across the country.
View Article and Find Full Text PDFArticle Synopsis
- The study investigates early onset multiple sclerosis (MS) in Brazilian patients diagnosed before age 18, highlighting the challenges in diagnosis and management.
- Data was collected retrospectively from 20 MS units across 11 states, resulting in 117 cases, with a mean onset age of 13.7 years and an average disease duration of 10 years.
- Overall, while some cases were severe, most patients with pediatric MS in Brazil exhibited relatively mild symptoms, with low disability levels and an average relapse rate of one episode every 2.5 years.
Background And Objective: Women with multiple sclerosis (MS) who intend to get pregnant are often advised to discontinue disease modifying therapy (DMT) prior to conception. This recommendation is not based on medical evidence and may interfere with disease control by immunomodulatory drugs. The present study was designed to help discuss the effect of DMT for MS on pregnancy and on disease course.
View Article and Find Full Text PDF